The severity of cerebral palsy symptoms varies widely, but most patients who have cerebral palsy have spasticity.

Spasticity is velocity-dependent resistance that affects muscle movement by increasing deep tendon reflexes and clonus. Spasticity can be caused by a dysfunction in the baseline inhibitory signals to the stretch reflex, so muscles are stiff and move-ments are often jerky and awkward. Consequently, even the simplest activities of daily living—walking, using hands, talking, swallowing—may be affected. Additionally, the constant stress and abnormal growth forces associated with spasticity may cause muscle and joint contractures, as well as skeletal deformities. Successfully managing spasticity can increase function and quality of life while reducing deformity.

At Gillette Children’s Specialty Healthcare, we provide a range of spasticity treatments to meet our patients’ varied needs.

Spectrum of Spasticity Care

Our spasticity treatment decisions are based on a variety of factors, including the following: the patient’s age, severity of spasticity and Gross Motor Function Classification System (GMFCS) level. We also consider the patient’s goals, along with the family’s access to follow-up care and ability to comply with the treatment recommendations. To meet patients’ individual needs, we provide a range of treatments, and we may recommend combining treatments to effectively manage spasticity (see the case study on P. 3).

The spasticity management options Gillette offers include the following therapy (physical, occupational and/or speech); bracing and splinting; oral or injected medications like botulinum toxin A; and surgical procedures such as implanting an intrathecal baclofen pump or performing a selective dorsal rhizotomy.

Case study - Multiple therapies

A Range of Treatment Options Individualizes Spasticity Management

by Angela Sinner, D.O., pediatric rehabilitation medicine specialist and Debbie Song, M.D., pediatric neurosurgeon

In the United States, cerebral palsy occurs in approximately two children per 1,000, and as many as 1 million people are affected. Cerebral palsy is a motor disorder affecting movement, posture and balance. It may be accompanied by disturbances of sensation, cognition, communication, perception, behavior and, potentially, seizures. The severity of these symptoms varies widely. However, 70 to 80 percent of patients who have cerebral palsy have spasticity.

Botulinum toxin A and phenol injections are well-suited for reducing focal tone issues or in the patient too young for more generalized tone reduction treatments. They can also be used in combination with other spasticity treatments.

Selecting dorsal rhizotomy is a procedure that permanently reduces spasticity by cutting the nerve rootlets that transmit the abnormal signals associated with spasticity.

Intrathecal baclofen therapy is used to provide a generalized reduction in tone. The implanted pump is refilled in clinic every few months, depending on the patient’s medication requirements.

Angela Sinner, D.O.
Pediatric Rehabilitation Medicine

Angela Sinner, D.O., specializes in pediatric rehabilitation medicine with a special interest in spina bifida, neurotrauma, and spasticity management. She received her doctor of osteopathic medicine degree from Des Moines University College of Osteopathic Medicine in Des Moines, Iowa. She completed a physical medicine and rehabilitation residency at the University of Minnesota Medical School in Minneapolis, and then completed specialized training at Gillette Children’s Specialty Healthcare through a fellowship in pediatric rehabilitation medicine. She has made numerous professional presentations on topics including pediatric concussion, posterior fossa syndrome, autonomic dysfunction in severe traumatic brain injury, and spinal cord injury evaluation. Her recent research has focused on intrathecal baclofen pump management as well as hyperkalemic incidence and treatment in spinal cord injury.

Debbie Song, M.D.
Pediatric Neurosurgeon

Debbie Song, M.D. is a pediatric neurosurgeon who treats patients who have spina bifida, and brain and spinal cord injury. She has a special interest in spina bifida, and brain and spinal cord injury. She has made numerous professional presentations on topics including pediatric concussion, posterior fossa syndrome, autonomic dysfunction in severe traumatic brain injury, and spinal cord injury evaluation. Her recent research has focused on intrathecal baclofen pump management as well as hyperkalemic incidence and treatment in spinal cord injury.

Debbie Song, M.D. performing a selective dorsal rhizotomy surgery. Debbie Song, M.D. performing a selective dorsal rhizotomy surgery.
Some patients will require a combination of treatments to effectively manage their spasticity (see the case study on P. 3). To relieve spasticity, we may prescribe some or all of the treatments below.

**Nonsurgical Treatments**

Oral medications include benzodiazepines like diazepam (Valium) and muscle relaxants such as dantrolene (Danotrile) or baclofen (Lioresal). At times, dopaminergic drugs such as levodopa/carbidopa (Sinemet) and trihexyphenidyl (Artane) may be used to treat increased muscle tone. Oral medications are chosen based on the individual's tone type, other symptoms and tolerance. We begin with low doses and gradually increase them as needed. If a drug must be discontinued, we taper it off, avoiding the complications associated with rapid withdrawal.

Injectable medications like botulinum toxin A (Botox) decrease muscle spasticity, which can allow us to help improve range of motion and mobility. This medication is best for addressing focal tone issues or if the patient is too young for more generalized tone reduction treatments. Botulinum toxin A works at the neuromuscular junction to inhibit acetylcholine release. Once the drug has been administered into a muscle, the patient can more readily participate in physical or occupational therapy and be fitted for braces or splints. The effects of Botox typically last for approximately six months.

**Neurosurgeical Treatments**

Prior to recommending a neurosurgical intervention, an interdisciplinary team (a neurosurgeon, a pediatric rehabilitation medicine specialist and an orthopedic surgeon) evaluates the patient. As part of the assessment, the patient undergoes a physical therapy evaluation and a gait and motion analysis. The team discusses a course of treatment with the family and may recommend a surgical intervention.

**Intrathecal baclofen therapy (ITB)** is a drug delivery system that consists of a pump implanted in the abdomen and a catheter whose tip delivers liquid baclofen (Lioresal) directly to the intrathecal space (where the spinal cord, nerve roots and cerebrospinal fluid are contained). Because the medication is administered intrathecally, a much smaller dose is needed to reduce spasticity than is required when the oral medication is used. ITB therapy is well suited for patients who require a generalized reduction in tone or whose goals include a focus on functional changes.

The therapy is also helpful for increasing patient comfort, reducing pain and making it easier to manage activities of daily living, such as dressing.

An external programmer is used to set the pump so it delivers the specified dose of baclofen. The amount can be adjusted to achieve an optimal therapeutic effect.

The pump is refilled with baclofen every few months in an outpatient setting. The timing of the refills depends upon a patient’s dosage requirements, the concentration of medication used and the size of the pump implanted. Because the pump has limited battery life, it must be surgically replaced and replaced with a new pump after five to seven years.

**Selective dorsal rhizotomy (SDR)** surgery permanently removes spinal sensory information by interrupting abnormal signals being carried through the sensory or dorsal nerve roots to the spinal cord. The concept of SDR is to reduce high muscle tone by cutting portions of the nerve roots that carry abnormal signals.

During SDR, the lumbar nerve roots that transmit information to and from the muscles of the lower extremities are identified. Each individual sensory nerve root that carries information from the spine and the vertebrae (somatic sensory) is then separated into 50 to 30 smaller threadlike rootlets, and each of the tiny rootlets is electrically stimulated. Rootlets that contribute to a child’s increased muscle tone are identified by the abnormal electromyographic and/or clinical response secured in the muscles of the legs. The rootlets that demonstrate an abnormal response when stimulated are cut, while the rootlets that trigger normal responses when stimulated are not cut. Usually, 20 to 40 percent of the nerve rootlets are cut.

The procedure may be done for patients who have spastic diplegic cerebral palsy, are 4 to 10 years old, and are typically at GMFCS levels I, II or III. Usually, children assessed at these levels have impairments affecting their lower extremities, but can walk independently or with the help of a walker or crutches. For more information about patient selection for SDR, see Trost J P, Schwartz M H, Krach L E, Dunn M E, and Novack T F. Comprehensive short-term outcome assessment of selective dorsal rhizotomy. Development Medicine & Child Neurology 2008, 50: 765-772.

**Rehabilitation and Orthopedic Interventions Following SDR**

After an SDR, reduces spasticity and tone, patients require intensive rehabilitation so they can relearn muscle patterning at Gillette, we recommend an extended inpatient rehabilitation stay. Children work on stretching, strengthening and movement. Therapy begins at a basic level: patients work on core strength and basic gross motor movements and positioning, and their therapy is adjusted as they progress. Typically, patients continue intense outpatient rehabilitation therapy after discharge.

Approximately one to two years after a rhizotomy, our orthopedic surgeons reassess the child’s gait and any orthopedic deformities. If required, our orthopedists may perform a single event multilevel surgery (SEMLS) to correct muscle contractures, bone deformities, weakened, poor muscle control, impaired balance or other problems associated with cerebral palsy. SEMLS will also be followed by rehabilitation therapy.

**Conclusion**

Although most patients who have cerebral palsy also have spasticity, the severity of the spasticity varies widely. Typically, there are a number of treatments to reduce spasticity and tone, enhance comfort and improve function. Having a range of spasticity management options allows us to determine which treatments work best for addressing focal tone issues or if the patient is too young for more generalized tone reduction treatments. Botulinum toxin A is widely associated with significant spasticity and dystonia of the lower extremities, and she has mixed tone in her trunk. Consequently, the decision to perform one of her (flushing and dressing) is difficult. When she was 2 years old, she began receiving botulinum toxin A injections. When she was 10 years old, the decision to perform SEMLS was made. She would have an intrathecal baclofen pump implanted to manage the spasticity in her lower extremities. Botulinum toxin A or phenol injections could also be used, as needed, to reduce the tone in her upper extremities.

During the baclofen pump implant procedure, the catheter tip was placed in her lower thoracic spine, and flow was established. The pump was placed on the right side in the abdominal area, and the catheter was tunneled from the pump and the catheter tip. The pump was filled with baclofen at 500 mcg/mL concentration. After a priming bolus, it was programmed to run at 100 mcg/day, and the pump and catheter were wired. The catheter was closed. The patient did not experience any complications postoperatively. The tone in her lower extremities was significantly improved. Periodically during the next few years, she also received botulinum toxin A injections to help reduce the spasticity in her trunk and extremities.

When she was 10 years old, a baclofen pump replacement was planned. Because the patient needed refills at 60-day intervals instead of the more customary 90-day intervals, the pump battery was depleted faster. She was implanted with a new larger pump (40 mL size), and it was connected to the existing catheter, which was still intact. Postoperatively, she had reduced spasticity in her lower extremities, so she could sit more comfortably in her wheelchair. She was then removed from the baclofen pump and patients, she received botulinum toxin A or phenol injections as needed to address the spasticity in her shoulder and torso.

---

www.emedicinehealth.com/cerebral_palsy/article_em.htm, accessed 05/02/12
Some patients will require a combination of treatments to effectively manage their spasticity (see the case study on P. 3). To relieve spasticity, we may prescribe some or all of the following medications:

**Oral Medications**

- Phenytoin (Dilantin) or carbamazepine (Tegretol) are used to treat increased muscle tone. Oral medications are chosen based on the individual's tone, symptoms, and response to other therapies. If a patient does not respond to oral medications, they may be considered for a surgical intervention.

**Botulinum toxin A (BTX-A)**

- This medication is also used to treat increased muscle tone. BTX-A injections work by temporarily weakening muscles, reducing spasticity, and improving range of motion and mobility. This medication is widely available and is effective in treating patients with cerebral palsy who have spasticity and tone. The location of the injection is based on a patient's needs and goals, and the dosage depends on the patient's size and prior response to the medication. To relieve spasticity, we may prescribe some or all of the following medications:

**Neurosurgical Treatments**

- Some patients will require a combination of treatments to effectively manage their spasticity (see the case study on P. 3). To relieve spasticity, we may prescribe some or all of the following medications:

**Phenol neurolysis**

- Phenol is dripped directly on the nerve roots that carry abnormal signals. When the nerves are exposed, a solution of phenol is dripped directly on the nerve roots that carry abnormal signals. The rootlets that demonstrate an abnormal response when stimulated are cut, while the rootlets that trigger normal signals are left intact. Some patients will require a combination of treatments to effectively manage their spasticity (see the case study on P. 3). To relieve spasticity, we may prescribe some or all of the following medications:

**Intrathecal baclofen therapy (ITB)**

- ITB is a drug delivery system that consists of a pump implanted in the abdomen and a catheter whose tip delivers intrathecal baclofen (Lioresal) directly to the intrathecal space (where the spinal cord, nerve roots, and cerebrospinal fluid are contained). Because the medication is administered intrathecally, a much smaller dose is needed to reduce spasticity than is required when the oral medication is used. ITB therapy is well suited for patients who require a generalized reduction in tone or whose goals include a focus on functional changes.

**Pharmacologic approaches**

- The drug is administered intrathecally so that the medication is delivered directly to the spinal cord. The pump is refilled with baclofen every few months in an outpatient setting. The patients undergo a physical therapy evaluation and a pain and motion analysis. The team discusses a course of treatment with the family and may recommend a surgical intervention.

**Selective dorsal rhizotomy (SDR)**

- Approximately one to two years after a rhizotomy, our orthopedists may perform a single event multilevel surgery (SEMLS) to correct muscle contractions in the legs and feet. The SDR procedure is performed on one side of the body, and the patient is typically discharged the same day. The surgery involves cutting nerve roots that carry abnormal signals. The procedure may be done for patients who have spastic diplegic cerebral palsy, are 4 to 10 years old, and are typically at GMFCS levels II, I, or III. Usually, children assessed at those levels have impairments affecting their lower extremities, but can walk independently or with the help of a walker or crutches. For more information about patient selection for SDR, see Trost J P, Schwartz H M, Krach L E, Dunn M E, and Novacheck T F. Comprehensive short-term outcome assessment of selective dorsal rhizotomy. Development Medicine & Child Neurology 2008, 50: 761-771.

**Rehabilitation and Orthopedic Interventions Following SDR**

- After an SDR, patients require intense rehabilitation so they can return to normal activities. Patients are usually sedated in the operating room to undergo the SDR surgery. As part of the assessment, the children undergo a physical therapy evaluation and a pain and motion analysis. The team discusses a course of treatment with the family and may recommend a surgical intervention.

**Conclusion**

- Although most patients who have cerebral palsy also have spasticity in their lower extremities, not all children with cerebral palsy have spasticity in their lower extremities, and it is not uncommon for some children to have spasticity in their lower extremities and dystonia of their upper extremities. When she was 2 years old, she began receiving botulinum toxin A injections. When she was 8 years old, the decision was made to combine pharmacologic and surgical interventions. She would have an intrathecal baclofen pump implanted to manage the spasticity in her lower extremities. Botulinum toxin A or phenol injections could also be used, as needed, to reduce the tone in her upper extremities. During the baclofen pump implant procedure, the catheter tip was placed in her lower thoracic spine, and flow was established. The pump was placed on the right side in the abdominal area, and the catheter was tunneled from the pump to the catheter tip. The pump was filled with baclofen at 500 mcg/mL concentration. After a priming bolus, it was programmed to run at 100 mcg/day with simple continuous flow. The pump was filled with baclofen at 500 mcg/mL concentration. After a priming bolus, it was programmed to run at 100 mcg/day with simple continuous flow. The tip of the pump was connected to a pump controller, and the catheter and pump were connected and secured. Both wound areas were closed. The patient did not experience any complications postoperatively. The tone in her lower extremities was not significantly improved. Periodically during the next few years, she also received botulinum toxin A injections to help reduce the spasticity in her trunk and extremities. When she was 10 years old, a baclofen pump replacement was planned. Because the patient needed refills at 60-day intervals instead of the more customary 30-day intervals, the pump battery was depleted faster. She was implanted with a new larger pump (42 mL size), and it was connected to the existing catheter, which was still intact. Postoperatively, she had reduced spasticity in her lower extremities, so she could sit more comfortably in her wheelchair. She will continue to receive botulinum toxin A or phenol injections as needed to address the spasticity in her shoulder and torso.

**Multiple Therapies Used to Manage Spasticity**

- A female patient has diffuse tone abnormalities as a result of schizencephaly. Her quadriplegic cerebral palsy is associated with significant spasticity and dystonia of the lower extremities, and she has mixed tone in her trunk. Consequently, one case of her (bathing and dressing) is difficult. When she was 2 years old, she began receiving botulinum toxin A injections. When she was 8 years old, the decision was made to combine pharmacologic and surgical interventions. She would have an intrathecal baclofen pump implanted to manage the spasticity in her lower extremities. Botulinum toxin A or phenol injections could also be used, as needed, to reduce the tone in her upper extremities.
Some patients will require a combination of treatments to effectively manage their spasticity (see the case study on P. 3). To relieve spasticity, we may prescribe some or all of the treatments below.

Non-surgical Treatments

Oral medications include benzodiazepines like diazepam (Valium) and muscle relaxants such as dantrolene (Dramine) or baclofen (Lioresal). At times, dopamine agonists such as levodopa/carbidopa (Sinemet) and trihexyphenidyl (Artane) may be used to treat increased muscle tone. Oral medications are chosen based on the individual’s tone type, other symptoms and tolerance. We begin with low doses and gradually increase them as needed. If a drug must be discontinued, we taper it off, avoiding the complications associated with rapid withdrawal.

Injectable medications like botulinum toxin A (Botox) decrease muscle spasticity, which can allow us to help improve range of motion and mobility. This medication is best for addressing focal tone issues or if the patient is too young for more generalized tone reduction treatments. Botulinum toxin A works at the neuromuscular junction to inhibit acetylcholine release. Once the drug has been administered, the patient can more readily undergo a physical therapy evaluation and a gait and motion analysis. The team discusses a course of treatment with the family and may recommend a surgical intervention.

Intra-cranial baclofen therapy (ITB) is a drug delivery system that consists of a pump implanted in the abdomen and a catheter whose tip delivers liquid baclofen (Lioresal) directly to the intra-cranial space (where the spinal cord, nerve roots and cerebrospinal fluid are contained). Because the medication is administered intrathecally, a much smaller dose is needed to reduce spasticity than is required when the oral medication is administered. ITB therapy is well suited for patients who require a generalized reduction in tone or whose goals include a focus on functional changes. The therapy is also helpful for increasing patient comfort, reducing pain and making it easier to manage activities of daily living, such as dressing.

An external programmer is used to set the pump so it delivers the specified dosage of baclofen. The amount can be adjusted to achieve an optimal therapeutic effect. The pump is refilled with baclofen every few months in an outpatient setting. Prior to recommending a neurosurgical intervention, an interdisciplinary team (a neurosurgeon, a pediatric orthopedic surgeon and a physical therapist) evaluates the patient. As part of the assessment, the patient undergoes a physical therapy evaluation and a gait and motion analysis. The team discusses a course of treatment with the family and may recommend a surgical intervention.

Neurosurgical Treatments

Prior to recommending a neurosurgical intervention, an interdisciplinary team (a neurosurgeon, a pediatric orthopedic surgeon and an orthopedic surgeon) evaluates the patient. As part of the assessment, the patient undergoes a physical therapy evaluation and a gait and motion analysis. The team discusses a course of treatment with the family and may recommend a surgical intervention.

Close-up of a Selective Dorsal Rhizotomy

The edges of the split (yellow) are separated and the exposed nerve rootlets are divided into five to 30 smaller threadlike rootlets, each of which triggers abnormal signals.

During SDR, the lumbar nerve roots that transmit information to and from the muscles of the lower extremities are identified. Each individual sensory nerve root that carries information from the skin and muscles to the spinal cord is then separated into five to 30 smaller threadlike rootlets, and each of the tiny rootlets is electrically stimulated. Rootlets that contribute to a child’s increased muscle tone are identified by the abnormal electromyographic and/or clinical response recorded in the muscles of the legs. The rootlets that demonstrate an abnormal response when stimulated are cut, while the rootlets that trigger normal responses when stimulated are not cut. Usually, 30 to 40 percent of the nerve rootlets are cut.

The procedure may be done for patients who have spastic diplegic cerebral palsy, ages 4 to 10 years old, and are typically at GMFCS levels I, II or III. Usually, children assessed at these levels have impairments affecting their lower extremities, but can walk independently or with the help of a walker or crutches. For more information about patient selection for SDR, see Trout J-P, Schwartz M-H, Krach L-E, Dunn M-E, and Novack T-F. Comprehensive short-term outcome assessment of selective dorsal rhizotomy. Developmental Medicine & Child Neurology 2008; 50: 761-771.

The surgery lasts for two years after a rhizotomy, our orthopedic surgeons reassess the child’s gait and any orthopedic deformities. If required, our orthopedists may perform a single event multilevel surgery (SEMLS) to correct muscle contractions, bone deformities, weakness, poor motor control, impaired balance or other problems associated with cerebral palsy. SEMLS will also be followed by rehabilitation therapy.

Conclusion

Although most patients who have cerebral palsy also have spasticity, the severity of the spasticity varies widely. Typically, there are a number of treatments to reduce spasticity and tone, enhance comfort and improve function. Having a range of physical therapy treatment options allows our therapists to select the appropriate care and match treatments with each patient’s condition and goals.  

Multiple Therapies Used to Manage Spasticity

A female patient has diffuse tone abnormalities as a result of schizophrenia. Her quadriplegic cerebral palsy is associated with significant spasticity and dystonia of her lower extremities, and she has mixed tone in her trunk. Consequently, the task of case care (her brushing and dressing) is difficult. When she was 2 years old, she began receiving botulinum toxin A injections. When she was 8 years old, the decision was made to combine botulinum toxin A and phenol injections as needed, to reduce the tone in her upper extremities.

During the baclofen pump implant procedure, the catheter tip was placed in her lower thoracic spine, and flow was established. The pump was placed with baclofen at 500 mcg/mL concentration. After a priming bolus, it was programmed to run at 100 mcg/day with simple continuous flow. The pump was filled with baclofen at 500 mcg/mL concentration. After a priming bolus, it was programmed to run at 100 mcg/day with simple continuous flow. The pump was placed in her lower thoracic spine, and flow was established. The pump was filled with baclofen at 500 mcg/mL concentration. After a priming bolus, it was programmed to run at 100 mcg/day with simple continuous flow. The pump was connected to the existing catheter and pump were connected and secured. Both wounds were closed. The patient did not experience any complications postoperatively. The tone in her lower extremities was significantly improved. Periodically during the next few years, she also received botulinum toxin A injections to help reduce the spasticity in her trunk and extremities.

When she was 10 years old, a baclofen pump replacement was planned. Because the patient needed refills at 60-day intervals instead of the more customary 30-day intervals, the pump battery was depleted faster. She was implanted with a new longer pump (42 mL size), and it was connected to the existing catheter, which was still intact. Postoperatively, she had reduced spasticity in her lower extremities, so she could sit more comfortably in her wheelchair. She will continue to receive both botulinum toxin A and phenol injections as needed to address the spasticity in her shoulder and torso.
A Range of Treatment Options Individualizes Spasticity Management

by Angela Sinner, D.O., pediatric rehabilitation medicine specialist and Debbie Song, M.D., pediatric neurosurgeon

In the United States, cerebral palsy occurs in approximately two children per 1,000, and as many as 1 million people are affected. Cerebral palsy is a motor disorder affecting movement, posture and balance. It may be accompanied by disturbances of sensation, cognition, communication, perception, behavior and, potentially, seizures. The severity of these symptoms varies widely. However, 70 to 80 percent of patients who have cerebral palsy have spasticity.

Spasticity is velocity-dependent resistance that affects muscle movement by increasing deep tendon reflexes and clonus. Spasticity can cause a disturbance in the baseline inhibitory signals to the stretch reflex, so muscles are stiff and movements are often jerky and awkward. Consequently, even the simplest activities of daily living—walking, using hands, talking—may be affected. Additionally, the constant stress and abnormal growth forces associated with spasticity may cause muscle and joint contractures, as well as skeletal deformities. Successfully managing spasticity can increase function and quality of life, while reducing deformity. At Gillette Children’s Specialty Healthcare, we provide a range of spasticity treatments to meet our patients’ varied needs.

Spectrum of Spasticity Care

Our spasticity treatment decisions are based on a variety of factors, including the following: the patient’s age, severity of spasticity and Gross Motor Function Classification System (GMFCS) level. We also consider the patient’s goals, along with the family’s access to follow-up care and ability to comply with the treatment recommendations. To meet patients’ individual needs, we provide a range of treatments, and we may recommend combining treatments to effectively manage spasticity (see the case study on P. 3).

The spasticity management options Gillette offers include the following therapy (physical, occupational and/or speech): bracing and splinting; oral or injected medications like botulinum toxin A; and surgical procedures such as implanting an intrathecal baclofen pump or performing a selective dorsal rhizotomy.

KEY INSIGHTS

- The severity of cerebral palsy symptoms varies widely but most patients who have cerebral palsy will have spasticity.
- Oral medications to control spasticity will be chosen based on the individual’s tone type, other symptoms and tolerances.
- Botulinum toxin A and phenol injections are well-suited for reducing focal tone issues of the patient who is too young for more generalized tone reduction treatments. They can also be used in combination with other spasticity treatments.
- Intrathecal baclofen therapy is used to provide a generalized reduction in tone. The implanted pump is refilled in clinic every few months, depending on the patient’s medication requirements.
- Selective dorsal rhizotomy is a procedure that permanently reduces spasticity by cutting the nerve roots that transmit the abnormal signals associated with spasticity.
A Range of Treatment Options Individualizes Spasticity Management

by Angela Sinner, D.O., pediatric rehabilitation medicine specialist and Debbie Song, M.D., pediatric neurosurgeon

In the United States, cerebral palsy occurs in approximately two children per 1,000, and as many as 1 million people are affected. Cerebral palsy is a motor disorder affecting movement, posture and balance. It may be accompanied by disabilities of sensation, cognition, communication, perception, behavior, and, potentially, seizures. The severity of these symptoms varies widely. However, 70 to 80 percent of patients who have cerebral palsy have spasticity. Spasticity is velocity-dependent resistance that affects muscle movement by increasing deep tendon reflexes and clonus. Spasticity is caused by a disruption in the baseline inhibitory signals to the stretch reflex, so muscles are stiff and movements are often jerky and awkward. Consequently, even the simplest activities of daily living—walking, using hands, talking, swallowing—may be affected. Additionally, the constant stress and abnormal growth forces associated with spasticity can cause muscle and joint contractures, as well as skeletal deformities. Successfully managing spasticity can increase function and quality of life, while reducing deformity.

At Gillette Children’s Specialty Healthcare, we provide a range of spasticity treatments to meet our patients’ varied needs. Our spasticity treatment decisions are based on a variety of factors, including the following: the patient’s age, severity of spasticity and Gross Motor Function Classification System (GMFCS) level. We also consider the patient’s goals, along with the family’s access to follow-up care and ability to comply with the treatment recommendations. To meet patients’ individual needs, we provide a range of treatments, and we may recommend combining treatments to effectively manage spasticity (see the case study on P. 3).

The spasticity management options Gillette offers include the following therapies: botulinum toxin A; and surgical procedures such as implanting an intrathecal pump to perform a selective dorsal rhizotomy. The severity of cerebral palsy symptoms varies widely, but most patients who have cerebral palsy will also have spasticity. Oral medications to control spasticity will be chosen based on the individual’s tone type, other symptoms and tolerances. Botulinum toxin A and phenol injections are well-suited for reducing focal tone issues or if the patient is too young for more generalized tone reduction treatments. They can also be used in combination with other spasticity treatments. Intrathecal baclofen therapy is used to provide a generalized reduction in tone. The implanted pump is refilled in clinic every few months, depending on the patient’s medication requirements.

Gillette Children’s Specialty Healthcare is now ranked 12th in the nation for orthopedics and 39th in the nation for pediatric neurology/neurosurgery at U.S. News Media Group’s 2012-2013 Best Children’s Hospitals rankings. Last year, Gillette ranked 25th and 49th in the two areas.